We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01746251
Recruitment Status : Unknown
Verified July 2020 by Lecia V. Sequist, Massachusetts General Hospital.
Recruitment status was:  Active, not recruiting
First Posted : December 10, 2012
Last Update Posted : July 7, 2020
Sponsor:
Collaborator:
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Lecia V. Sequist, Massachusetts General Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Unknown
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2021